Literature DB >> 31286780

Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the 'Rete Ematologica Pugliese E Basilicata'.

Giuseppe Mele1, Domenico Pastore1, Nicola Di Renzo2, Alberto Fragasso3, Attilio Guarini4, Patrizio Mazza5, Pellegrino Musto6, Vincenzo Pavone7, Giuseppe Tarantini8, Paola Curci9, Antonietta Pia Falcone10, Anna Mele7, Maria Rosanna Miccolis8, Giulia Palazzo5, Gaetano Palumbo11, Angela Maria Quinto4, Giovanni Reddiconto2, Rita Rizzi9, Nicola Cascavilla10, Giorgina Specchia9, Silvana Franca Capalbo11.   

Abstract

Entities:  

Year:  2019        PMID： 31286780     DOI： 10.1080/10428194.2019.1636989

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  4 in total

Review 1.  Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results.

Authors:  Luca Bertamini; Giuseppe Bertuglia; Stefania Oliva
Journal:  Front Oncol       Date:  2022-05-11       Impact factor: 5.738

2.  Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials.

Authors:  Tobias Dechow; Ali Aldaoud; Timo Behlendorf; Wolfgang Knauf; Henning Eschenburg; Matthias Groschek; Richard Hansen; Ulrike Söling; Sina Grebhardt; Hans Ulrich Siebenbach; Corinne Vannier; Karin Potthoff
Journal:  Eur J Haematol       Date:  2021-11-15       Impact factor: 3.674

3.  Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan.

Authors:  Yu-Chin Hung; Jyh-Pyng Gau; Shang-Yi Huang; Bor-Sheng Ko; Chieh-Lin Jerry Teng
Journal:  Front Oncol       Date:  2021-05-28       Impact factor: 6.244

4.  Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.

Authors:  Marina Silvia Parisi; Salvatore Leotta; Alessandra Romano; Vittorio Del Fabro; Enrica Antonia Martino; Valeria Calafiore; Rachele Giubbolini; Uros Markovic; Valerio Leotta; Mary Ann Di Giorgio; Daniele Tibullo; Francesco Di Raimondo; Concetta Conticello
Journal:  J Clin Med       Date:  2019-10-16       Impact factor: 4.241
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.